GlassScriptPhysician profile
James R Hill
NPI 1881059244
$9,134.32
in general payments reported to CMS, 2019-2025
29 companies · $728 in 2025
The $728 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,883 · 2022: $2,693 · 2023: $2,097 · 2024: $733 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873 · Travel and Lodging: $640 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.72 |
| Travel and Lodging | $639.95 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,108.83 | 2021-2023 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $920.54 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Boston Scientific Corporation | $853.60 | 2021-2024 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $844.99 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $792.33 | 2021-2023 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $608.45 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $464.76 | 2021-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $415.20 | 2021-2024 | Verquvo |
| Pfizer INC. | $351.70 | 2021-2024 | |
| Amgen INC. | $334.88 | 2021-2024 | Repatha |
| Esperion Therapeutics, INC. | $267.55 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.89 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $229.13 | 2021-2024 | Lifevest |
| Chiesi USA, INC. | $216.62 | 2021-2023 | Kengreal, Cleviprex |
| Novo Nordisk INC | $97.54 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.65 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $40.11 | 2023 | Arcalyst |
| Nalu Medical, INC. | $38.27 | 2025 | Nalu Neurostimulation System |
| Amarin Pharma, INC. | $33.41 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $31.26 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $29.81 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Inari Medical, INC. | $26.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.01 | 2023 | Onpattro |
| Amryt Pharma Holdings LTD | $25.35 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $22.03 | 2023 | Inpefa |
| Abbott Laboratories | $21.35 | 2024 | Cardiomems |
| Baxter Healthcare | $19.91 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $13.44 | 2023 | Uptravi, Opsumit |
| Astellas Pharma US INC | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.